Concord Biotech stock gains 3% as Kotak and Antique Broking issue positive coverage

Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.

Read More

Top 100 Best Sellers

​ Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels. Kotak Institutional Equities based on strong discounted cash flows and the company’s expertise in high entry barrier fermentation active pharmaceutical ingredients (API) segment sees a 15 percent upside potential from the current price levels.  Moneycontrol Latest News Read More